Sanofi-Aventis (SNY) Says Multaq Study Shows 24% Cut in Cardio Hospitalization/Death -Bloomberg
More News related to SNY
- BioMed Realty (BMR) To Lease 131K Sq. Ft. From Regeneron Pharma (REGN)
- Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center
- First Commercial Order for Changda International's Thiophene from French Drug Giant
- Sanofi-aventis (SNY) Signs Licensing Agreement with Intelliject
- Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America
Bloomberg is reporting that Sanofi-Aventis (NYSE: SNY) said Multaq results show statistical significance: Multaq reduced cardio hospitalization/death by 24%.
Related Categories
Corporate NewsStocks Mentioned
-0.14Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
